Diphenhydramine/lorazepam/zolpidem (developmental code name SM-1) is a combination of the antihistamine and anticholinergic diphenhydramine, the benzodiazepine lorazepam, and the Z drug/nonbenzodiazepine zolpidem which is or was under development for the treatment of insomnia. It is taken orally. Both lorazepam and zolpidem are GABAA receptor positive allosteric modulators. The combination was originated by Sequential Medicine and is under development by Eusol Biotech. As of October 2024, it is in phase 3 clinical trials for insomnia. However, another source lists the drug as having been discontinued.
See also List of investigational insomnia drugs
References